Skip to main content
I

INVEX THERAPEUTICS LTD — Investor Relations & Filings

Ticker · IXC ISIN · AU0000048621 ASX Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2026-04-23 Regulatory Filings
Country AU Australia
Listing ASX IXC

About INVEX THERAPEUTICS LTD

https://invextherapeutics.com

Invex Therapeutics Ltd focuses on the development and commercialization of treatments for neurological conditions associated with raised intracranial pressure. The company’s primary clinical program involves repurposing exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, specifically for Idiopathic Intracranial Hypertension (IIH). Its lead candidate, Presendin™, is a proprietary formulation of exenatide designed to inhibit cerebrospinal fluid production at the choroid plexus, effectively lowering intracranial pressure. Invex addresses a significant unmet medical need, as there are currently no regulatory-approved pharmacological treatments for IIH. The company is progressing its lead candidate through the IIH EVOLVE Phase III clinical trial, targeting improvements in headache disability and visual outcomes for patients suffering from this chronic condition.

Recent filings

Filing Released Lang Actions
Invex to Expand Preclinical Research Program 2 pages 191.4KB
Regulatory Filings Classification · 1% confidence The document is an ASX media release announcing the expansion of a preclinical research program. It is not an earnings release, financial report, AGM material, or any specific transaction notice. It is a general corporate update filed under continuous disclosure obligations, fitting the fallback category for miscellaneous regulatory announcements. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-04-23 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 669.6KB
Interim / Quarterly Report Classification · 1% confidence The document is an 'Appendix 4C' quarterly cash flow report combined with a quarterly activities report for Invex Therapeutics. In the Australian market (ASX), Appendix 4C filings are standard quarterly financial disclosures for entities not primarily engaged in mining or oil and gas exploration. Since it contains substantive financial data (cash flow statements) and operational analysis for a specific fiscal quarter, it falls under the definition of an Interim/Quarterly Report (IR). Q3 2026
2026-04-23 English
Resignation of Joint Company Secretary 1 page 134.5
Regulatory Filings
2026-03-22 English
Results of Meeting 2 pages 156.5KB
Regulatory Filings
2026-02-16 English
Appendix 4D and Half Year Report 19 pages 1.1MB
Regulatory Filings
2026-02-11 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 982.8KB
Regulatory Filings
2026-01-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.